As Featured in ITN Online:
Shoddy handling of biopsied tissue is an often unseen problem of breast cancer diagnosis, one that passes as a standard operating procedure yet can endanger the diagnosis and ultimately the life of a woman being examined for a suspicious breast lesion, according to Darwin Asa, Ph.D., senior product manager for tissue acquisition solutions at Leica Biosystems. Many radiology sites do not properly preserve biopsied tissue before it is sent to pathology, often placing biopsied tissue, Asa says, into jars of the preservative formalin with little consideration given to the integrity of the tissue. But Leica has come up with a solution – a specimen containment and transportation system called MammoPort.
The new product, released commercially in September and shown at the Mammotome booth in South Hall (3129) – (Mammotome is owned by Leica) – eliminates much of the handling of biopsied tissue by radiology technologists. In so doing MammoPort could bring pathology one step closer to enterprise-wide imaging, as it tightens the connection between radiology and pathology, and helps standardize the process of transferring breast biopsy tissue from the radiology suite to the pathology lab.
Rather than being placed haphazardly into a jar of formalin, the tissue is placed after needle extraction into tiny trays that can be X-rayed, placed in a plastic box that is then closed, immersed in formalin, and sent to pathology. This standardized tissue transfer from radiology to pathology promises to ensure quality and reduce errors.
– Greg Freiherr, Industry Consultant